147 related articles for article (PubMed ID: 29325849)
1. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Pandey D; Patel H; Ranvir R; Kadam S; Patel D; Bahekar R; Jain M
Chem Biol Interact; 2018 Feb; 282():13-21. PubMed ID: 29325849
[TBL] [Abstract][Full Text] [Related]
2. Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Bahekar R; Jain M
Biomed Pharmacother; 2018 Feb; 98():364-371. PubMed ID: 29275178
[TBL] [Abstract][Full Text] [Related]
3. Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Sutariya B; Patel M; Bahekar R; Jain MR
Drug Res (Stuttg); 2017 Dec; 67(12):730-736. PubMed ID: 28898910
[TBL] [Abstract][Full Text] [Related]
4. Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.
Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Bahekar RH; Jain MR
Curr Mol Pharmacol; 2019; 12(2):139-146. PubMed ID: 30747091
[TBL] [Abstract][Full Text] [Related]
5. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):35-43. PubMed ID: 29357809
[TBL] [Abstract][Full Text] [Related]
6. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Sutariya B; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Can J Physiol Pharmacol; 2018 Jun; 96(6):587-596. PubMed ID: 29406832
[TBL] [Abstract][Full Text] [Related]
7. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.
Patel VJ; Joharapurkar AA; Kshirsagar SG; Sutariya BK; Patel MS; Patel HM; Pandey DK; Bahekar RH; Jain MR
World J Diabetes; 2018 Jun; 9(6):80-91. PubMed ID: 29988851
[TBL] [Abstract][Full Text] [Related]
8. Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Savsani H; Bahekar R; Jain M
Drug Res (Stuttg); 2020 Aug; 70(8):376-384. PubMed ID: 32645724
[TBL] [Abstract][Full Text] [Related]
9. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.
Parlevliet ET; Wang Y; Geerling JJ; Schröder-Van der Elst JP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H; Rensen PC
PLoS One; 2012; 7(11):e49152. PubMed ID: 23133675
[TBL] [Abstract][Full Text] [Related]
11. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.
Taher J; Baker C; Alvares D; Ijaz L; Hussain M; Adeli K
Endocrinology; 2018 Sep; 159(9):3340-3350. PubMed ID: 30052880
[TBL] [Abstract][Full Text] [Related]
12. Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Shah K; Bahekar R; Shah GB; Jain MR
Drug Res (Stuttg); 2017 Jun; 67(6):318-326. PubMed ID: 28445900
[TBL] [Abstract][Full Text] [Related]
13. Effect of GLP-1 based therapies on diabetic dyslipidemia.
Patel VJ; Joharapurkar AA; Shah GB; Jain MR
Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.
Wang Y; Parlevliet ET; Geerling JJ; van der Tuin SJ; Zhang H; Bieghs V; Jawad AH; Shiri-Sverdlov R; Bot I; de Jager SC; Havekes LM; Romijn JA; Willems van Dijk K; Rensen PC
Br J Pharmacol; 2014 Feb; 171(3):723-34. PubMed ID: 24490861
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Panjwani N; Mulvihill EE; Longuet C; Yusta B; Campbell JE; Brown TJ; Streutker C; Holland D; Cao X; Baggio LL; Drucker DJ
Endocrinology; 2013 Jan; 154(1):127-39. PubMed ID: 23183176
[TBL] [Abstract][Full Text] [Related]
16. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.
Yao Y; Li Q; Wang W; Zhang J; Gao P; Xu Y
Cell Physiol Biochem; 2018; 50(2):679-693. PubMed ID: 30308521
[TBL] [Abstract][Full Text] [Related]
18. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Jall S; Sachs S; Clemmensen C; Finan B; Neff F; DiMarchi RD; Tschöp MH; Müller TD; Hofmann SM
Mol Metab; 2017 May; 6(5):440-446. PubMed ID: 28462078
[TBL] [Abstract][Full Text] [Related]
19. Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.
Patel V; Joharapurkar AA; Kshirsagar SG; Patel KN; Bahekar R; Shah G; Jain MR
Can J Physiol Pharmacol; 2016 Feb; 94(2):161-167. PubMed ID: 26629909
[TBL] [Abstract][Full Text] [Related]
20. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
